Abstract:Background: Cannabinoids bind to cannabinoid receptors type 1 and 2 and produce analgesia in several pain models, but central side effects from cannabinoid 1 receptors limit their clinical use. Because of the pain-relieving effects of cannabinoid 2 (CB2) receptor agonists in inflammation pain, incision pain, and neuropathic pain models, we tested whether spinal CB2 receptor activation would induce antihyperalgesia in cancer pain. Our previous study showed that the 2B subunit of N-methyl-D-aspartate (NR2B) receptor in the spinal cord participates in bone cancer pain in mice. In the present study, we also tested the cannabinoid effect on the expression of NR2B. Methods: Seventy-two mice were randomly allocated to 7 different groups: (1) control; (2) sham and tumor-bearing mice, which include (3) V; (4) J1; (5) J2; (6) J3; and (7) J4. In the groups of tumor-bearing mice, C(3)H/Hej mice were implanted with NCTC2472 fibrosarcoma cells into the femur bone to induce bone cancer-related pain behaviors. The sham mice were implanted with minimal essential medium α modification, whereas the control mice received no injection. On day 14 after implantation, tumor-invoked tactile allodynia and thermal hyperalgesia were assessed. Tumor-bearing mice were assigned to intrathecal administration of the CB2 receptor agonist JWH015 (0.5, 1, and 2 μg), CB2 receptor antagonist AM630 (2 μg), or vehicle, and the assessment of withdrawal thresholds was then performed. Tactile allodynia and thermal hyperalgesia were assessed before administration and at 1 hour, 6 hours, 12 hours, 24 hours, 48 hours, and 72 hours after administration. Spinal NR2B activation of all tumor-bearing mice at 12 hours and 72 hours were determined by reverse transcription-polymerase chain reaction analyses. Results: At day 14 after operation, tumor-evoked tactile allodynia and thermal hyperalgesia were higher in tumor-bearing mice compared with the sham and control mice. Intrathecal administration of JWH015 dose dependently attenuated tumor-evoked tactile allodynia and thermal hyperalgesia but this effect was prevented by intrathecal administration of AM630 30 minutes before. The mRNA expression of NR2B was similar to this result. At 12 hours after administration, the expression of NR2B mRNA in the spinal cord was lower in mice that were administered JWH015 compared with the vehicle group. However, this phenomenon was reversed in the group that was preadministered AM630. Conclusion: These data indicated that intrathecal administration of cannabinoid receptor agonists might relieve cancer pain, probably by reducing NR2B-dependent activity in the spinal cord. These results also suggested that cannabinoids might be a useful alternative or adjunct therapy for relieving cancer pain.

Intrathecal Injection of Selected Peptide Myr-RC-13 Attenuates Bone Cancer Pain by Inhibiting KIF17 and NR2B Expression

Intrathecal Injection of the Peptide Myr-NR2B9c Attenuates Bone Cancer Pain Via Perturbing N-Methyl-D-Aspartate Receptor-PSD-95 Protein Interactions in Mice

Analgesic Efficacy of Intrathecal Injection of Competitive Kinesin Superfamily Protein 17 Antagonist in a Mouse Model of Bone Cancer Pain

The Inhibitor of Calcium/calmodulin-Dependent Protein Kinase II KN93 Attenuates Bone Cancer Pain Via Inhibition of KIF17/NR2B Trafficking in Mice

The Role of N‐methyl‐d‐aspartate Receptor Subunit NR2B in Spinal Cord in Cancer Pain

Intrathecal Injection of Metabotropic Glutamate Receptor Subtype 3 and 5 Agonist/Antagonist Attenuates Bone Cancer Pain by Inhibition of Spinal Astrocyte Activation in a Mouse Model

Effects of Repeated Intrathecally KIF17 Antisense Oligodeoxynucleotide on the Expression of Mlin10 and NR2B in Spinal Cord in a Mouse Model of Bone Cancer Pain

Kinesin Superfamily Protein 17 Contributes to the Development of Bone Cancer Pain by Participating in Nr2b Transport in the Spinal Cord of Mice

Intrathecal Bone Marrow Stromal Cells Inhibit Neuropathic Pain Via TGF-β Secretion.

Involvement of the Spinal NMDA Receptor/pkcγ Signaling Pathway in the Development of Bone Cancer Pain

Relief of mechanical allodynia in rat model of bone cancer by intrathecal MCP-1 neutralizing antibody

Activation of Spinal Mrgc-Gi-Nr2b-Nnos Signaling Pathway by Mas Oncogene-Related Gene C Receptor Agonist Bovine Adrenal Medulla 8-22 Attenuates Bone Cancer Pain in Mice

Intrathecal administration of the cannabinoid 2 receptor agonist JWH015 can attenuate cancer pain and decrease mRNA expression of the 2B subunit of N-methyl-D-aspartic acid

Effect of intrathecal different dose of kinesin superfamily 17 on the development of bone cancer pain in mice

Intrathecal Injection of JWH-015 Attenuates Bone Cancer Pain Via Time-Dependent Modification of Pro-inflammatory Cytokines Expression and Astrocytes Activity in Spinal Cord.

Effect of Single Intrathecal Small Peptide Inhibitor of Mlin10-Pdz1 Domain on the Behavior of Mouse Models with Bone Cancer Pain

Antinociceptive Effect Of Intrathecal Microencapsulated Human Pheochromocytoma Cell In A Rat Model Of Bone Cancer Pain

Intrathecal Administration of Roscovitine Attenuates Cancer Pain and Inhibits the Expression of NMDA Receptor 2B Subunit Mrna

Neuropeptide Y is up-regulated and induces antinociception in cancer-induced bone pain

Protease-activated receptor 2 antagonist potentiates analgesic effects of systemic morphine in a rat model of bone cancer pain.

A Single Intrathecal or Intraperitoneal Injection of CB2 Receptor Agonist Attenuates Bone Cancer Pain and Induces a Time-Dependent Modification of GRK2